Investing RAD 202 receives approval to start Phase 1 therapeutic trial December 20, 2024 Share Share on Facebook Share on Twitter Pinterest Email Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com 0 Prev Post Completion of Tranche 1 of the Placement December 20, 2024 Next Post PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis December 20, 2024 Related Posts Editor’s Picks: Silver Price Hits 13 Year High, Gold Takes a Breather June 22, 2025 Tech 5: OpenAI/Microsoft Talks Get Tense, SoftBank Floats Arizona Robotics Hub June 22, 2025 Allied Critical Metals: Advancing Tungsten Projects in Portugal June 21, 2025
